What Is Hair Restoration

PRP (platelet-rich plasma) for hair restoration is a minimally invasive procedure in which a concentrated preparation of a patient's own platelets is injected into the scalp to stimulate hair follicle activity. The platelets release growth factors that promote blood vessel formation, extend the active growth phase of hair, and encourage miniaturized follicles to produce thicker strands. It is most commonly applied to androgenetic alopecia (male and female pattern hair loss) and is sometimes combined with microneedling or other treatments.

Hair loss affects a substantial portion of the adult population and is frequently linked to hormonal shifts, aging, nutritional status, and systemic inflammation. While cosmetic in appearance, thinning hair can serve as an external marker of underlying changes in hormonal balance, circulation, and tissue regeneration capacity. Addressing it through a regenerative lens, rather than purely cosmetic concealment, aligns with a broader interest in maintaining tissue vitality across the lifespan.

From a longevity perspective, PRP for hair sits at the intersection of regenerative medicine and aesthetic maintenance. The same growth factor signaling that drives hair follicle recovery, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), participates in wound healing and tissue repair throughout the body. Understanding how these pathways function in the scalp offers a window into regenerative capacity more broadly.

The procedure begins with a standard venous blood draw, typically 10 to 60 milliliters. This blood is placed in a centrifuge that separates it into layers: red blood cells settle to the bottom, platelet-poor plasma rises to the top, and a concentrated platelet layer (the "buffy coat") forms in between. The platelet-rich fraction is extracted and prepared for injection.

Platelets are cellular fragments that store alpha granules, which contain a dense payload of growth factors. When activated (either by the injection itself or by the addition of calcium chloride or thrombin), these granules release PDGF, VEGF, TGF-beta, epidermal growth factor (EGF), and insulin-like growth factor (IGF-1). In the scalp, these signaling molecules act on dermal papilla cells at the base of hair follicles. They promote angiogenesis (new capillary formation), which improves nutrient delivery to the follicular unit. They also shift follicles from the telogen (resting) phase into the anagen (active growth) phase and can increase the diameter of the hair shaft produced by miniaturized follicles.

The depth and pattern of injection matter. Practitioners typically use a grid pattern across thinning zones, injecting at the level of the dermal papilla (roughly 1 to 2 millimeters deep in the scalp). Some protocols combine PRP with microneedling to create controlled micro-injuries that amplify the local wound-healing response and allow growth factors to penetrate more evenly. The entire process relies on the body's own repair machinery; no synthetic drugs or foreign biological materials are introduced.

Multiple randomized controlled trials and systematic reviews have evaluated PRP for androgenetic alopecia. The overall weight of evidence suggests that PRP can increase hair density and hair shaft diameter compared to placebo (saline) injections, particularly in patients with early to moderate thinning. Several meta-analyses pooling data from these trials report statistically significant improvements in hair count, though the magnitude of benefit varies across studies. Heterogeneity is a significant limitation: preparation methods (single-spin vs. double-spin centrifugation, leukocyte-rich vs. leukocyte-poor formulations), platelet concentrations, injection depths, and treatment intervals differ substantially between protocols, making direct comparisons difficult.

Longer-term data remain limited. Most trials follow patients for six to twelve months, and few extend beyond that window. It is unclear how durable the results are without ongoing maintenance treatments, and head-to-head comparisons with established pharmacological therapies (minoxidil, finasteride) are still relatively sparse. Evidence for PRP in alopecia areata and other non-androgenetic forms of hair loss is weaker, consisting mostly of small case series and pilot studies. The field would benefit from standardized PRP preparation protocols and longer follow-up periods to clarify the optimal approach and durability of response.

Because PRP uses the patient's own blood, systemic adverse events are rare. Local side effects include scalp tenderness, transient swelling, and minor bruising at injection sites, all of which typically resolve within one to two days. Infection is possible, as with any injection, but reported incidence is very low. Individuals with platelet disorders, active infections, blood cancers, or anticoagulant use may face higher risk and should discuss candidacy with a qualified practitioner. PRP is not FDA-approved specifically for hair loss; it is used off-label, and insurance rarely covers the procedure.